Condition: Gastroenteropancreatic Neuroendocrine Tumor · Sponsor: Stanford University
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.
This description comes directly from the study's public registry record.
gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu · (650) 498-7757 · gpineda@stanford.edu
gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu · (650) 498-7757 · gitrialeligibility@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute Palo Alto | Stanford, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04609592